TLR7 and cancer: A combination of cyclophosphamide with either the TLR7/8 agonist (3M-011) or TLR7 agonists (852A) verified that cyclophosphamide did not negatively interfere with TLR agonists suppressing cancer but may actually potentiate the effect, depending on the dosing schedule [128].